$5.24 Billion is the total value of Perceptive Advisors's 278 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 86.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $42,154,000 | +17.9% | 277,252 | -0.0% | 0.80% | -55.3% |
| ACRX | Sell | ACELRX PHARMACEUTICALS INC | $11,450,000 | +42.7% | 2,489,216 | -33.3% | 0.22% | -45.8% |
| VSAR | Sell | VERSARTIS INC | $9,250,000 | -88.0% | 3,776,320 | -14.3% | 0.18% | -95.4% |
| CRBP | Sell | CORBUS PHARMACEUTICALS HLDGS | $5,928,000 | -23.6% | 829,368 | -32.7% | 0.11% | -71.1% |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $3,986,000 | +47.3% | 233,800 | -44.7% | 0.08% | -44.1% |
| PPHM | Exit | PEREGRINE PHARMACEUTICALS IN | $0 | – | -24,332 | -100.0% | -0.00% | – |
| ONSIZ | Exit | ONCOBIOLOGICS INC*w exp 05/18/201 | $0 | – | -462,500 | -100.0% | -0.00% | – |
| ONSIW | Exit | ONCOBIOLOGICS INCw exp 02/18/201 | $0 | – | -462,500 | -100.0% | -0.00% | – |
| ARNI | Exit | ARNO THERAPEUTICS INC | $0 | – | -4,177,577 | -100.0% | -0.01% | – |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -62,110 | -100.0% | -0.02% | – |
| DPLO | Exit | DIPLOMAT PHARMACY INC | $0 | – | -30,658 | -100.0% | -0.02% | – |
| INCR | Exit | INC RESH HLDGS INCcl a | $0 | – | -8,532 | -100.0% | -0.02% | – |
| ICLR | Exit | ICON PLC | $0 | – | -5,187 | -100.0% | -0.03% | – |
| MOH | Exit | MOLINA HEALTHCARE INC | $0 | – | -8,140 | -100.0% | -0.03% | – |
| ACOR | Exit | ACORDA THERAPEUTICS INC | $0 | – | -31,786 | -100.0% | -0.03% | – |
| HRC | Exit | HILL ROM HLDGS INC | $0 | – | -7,930 | -100.0% | -0.03% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -6,088 | -100.0% | -0.04% | – |
| LHCG | Exit | LHC GROUP INC | $0 | – | -10,730 | -100.0% | -0.04% | – |
| ONS | Exit | ONCOBIOLOGICS INC | $0 | – | -837,886 | -100.0% | -0.04% | – |
| WCG | Exit | WELLCARE HEALTH PLANS INC | $0 | – | -5,056 | -100.0% | -0.05% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -847,458 | -100.0% | -0.07% | – |
| CARA | Exit | CARA THERAPEUTICS INCcall | $0 | – | -100,000 | -100.0% | -0.08% | – |
| PSDV | Exit | PSIVIDA CORP | $0 | – | -1,149,556 | -100.0% | -0.10% | – |
| ADMP | Exit | ADAMIS PHARMACEUTICALS CORP | $0 | – | -400,000 | -100.0% | -0.10% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -20,000 | -100.0% | -0.11% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -723,853 | -100.0% | -0.12% | – |
| FWP | Exit | FORWARD PHARMA A/Ssponsored adr | $0 | – | -194,718 | -100.0% | -0.20% | – |
| UNH | Exit | UNITEDHEALTH GROUP INC | $0 | – | -28,480 | -100.0% | -0.27% | – |
| ANIP | Exit | ANI PHARMACEUTICALS INC | $0 | – | -125,399 | -100.0% | -0.30% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL INcall | $0 | – | -100,000 | -100.0% | -0.31% | – |
| AXGT | Exit | AXOVANT SCIENCES LTDcall | $0 | – | -300,000 | -100.0% | -0.35% | – |
| EGRX | Exit | EAGLE PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.40% | – |
| RDUS | Exit | RADIUS HEALTH INCput | $0 | – | -200,000 | -100.0% | -0.46% | – |
| ZYNE | Exit | ZYNERBA PHARMACEUTICALS INCput | $0 | – | -100,000 | -100.0% | -0.51% | – |
| AXGT | Exit | AXOVANT SCIENCES LTD | $0 | – | -572,700 | -100.0% | -0.67% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLC | $0 | – | -85,572 | -100.0% | -0.67% | – |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -645,873 | -100.0% | -1.47% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS | $0 | – | -1,089,961 | -100.0% | -1.85% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-05-01 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.